This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why Investors Should Retain Zimmer Biomet (ZBH) Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) owing to ongoing business recovery from the COVID-led pandemic impact.
Globus Medical (GMED) Global Growth Strong Despite Margin Woe
by Zacks Equity Research
Despite continued margin declines in Japan, Globus Medical (GMED) remains positive on the progress and potential of its international business for long-term growth as it continues to reset the market in the country.
Syneos Health (SYNH) Hurt by Low Reimbursable Expense, FX Issue
by Zacks Equity Research
Syneos Health (SYNH) experiences delays in large pharma award decisions, with net awards being impacted by greater-than-normal delays.
Neogen (NEOG) Rises 7.9% Since Q1 Earnings: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Neogen's (NEOG) recent product launches and strong global presence.
Neogen (NEOG) Benefits From Advanced Portfolio, Global Growth
by Zacks Equity Research
Barring Australia and China, solid international operations also buoy optimism for Neogen (NEOG).
Here's Why You Should Retain Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Hologic (HOLX), led by the continued strength of the GYN Surgical business.
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) on robust performances across the RMS and DSA segments.
Insulet's (PODD) Omnipod Sales Aid, Costs Continue to Rise
by Zacks Equity Research
Insulet (PODD) progresses well with respect to its four-pillar strategy, wherein the first two pillars include expanding access and awareness, and delivering consumer-focused innovation.
Abbott (ABT) to Upgrade PHCs Across India With New Pact
by Zacks Equity Research
Abbott's (ABT) HWC program is likely to benefit more than 2.5 million people from under-resourced communities annually.
Omnicell (OMCL) Ailed by Mounting Costs, Macroeconomic Issues
by Zacks Equity Research
Macroeconomic factors adversely affect bookings and revenues in Omnicell's (OMCL) point-of-care business. The company reduces its overall bookings and revenue outlook for the year.
SmileDirectClub (SDC) Gains From Innovation Amid Macro Issues
by Zacks Equity Research
A series of cutting-edge innovations, strategic distribution and insurance partnerships are added positives for SmileDirectClub (SDC).
Here's Why Investors Should Retain Thermo Fisher (TMO) Stock
by Zacks Equity Research
Investors are optimistic about Thermo Fisher's (TMO) continued strength across its certain end markets.
Here's Why You Should Retain Edwards Lifesciences (EW) Now
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW), led by strong underlying growth across all product groups.
Bio-Rad (BIO) Core Diagnostic Sales Grow Amid Supply Challenges
by Zacks Equity Research
Bio-Rad's (BIO) underlying Life Science currency-neutral core revenue growth is primarily driven by Western loading, qPCR, process media and antibody products sales.
Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) on strong growth in the base business.
Abbott's (ABT) FreeStyle Libre 3 Integrates With AID System
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre 3 integration with mylife Loop solutions will help build a smart, automated process to deliver insulin based on real-time glucose data.
Walgreens Boots (WBA) Gains From Digital Sales Amid Cost Woes
by Zacks Equity Research
Within the U.S. Healthcare segment, Walgreens Boots (WBA) is optimistic about the acquisition of CareCentrix.
Here's Why You Should Retain Boston Scientific (BSX) For Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX), led by new strategic investments and the robust performance of the WATCHMAN device.
Thermo Fisher's (TMO) Monkeypox Test Receives FDA EUA
by Zacks Equity Research
Thermo Fisher's (TMO) monkeypox test kit is a PCR test intended to spot non-variola Orthopoxviruses, including the monkeypox virus.
Abbott's (ABT) Eterna SCS System Receives FDA's Approval
by Zacks Equity Research
Abbott's (ABT) Eterna SCS technology shows 23% more pain reduction compared with traditional waveform technology approaches.
Edwards Lifesciences (EW) Rides on Innovation Amid Rising Costs
by Zacks Equity Research
Edwards Lifesciences (EW) expects to report underlying sales growth in the mid-single-digit range for 2022, banking on market growth and the adoption of premium technologies.
Charles River (CRL) Benefits From Price Rise Amid FX Woe
by Zacks Equity Research
Charles River's (CRL) RMS growth prospects are high, courtesy of accelerating growth for research model services and research models.
Here's Why Investors Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS (STE), led by strong segmental growth and the Cantel Medical acquisition.
Henry Schein (HSIC) Expands Dental Offerings With New Pact
by Zacks Equity Research
Henry Schein's (HSIC) latest deal expands its offering in several fast-growing product segments, including clinical software and oral surgery and orthodontic products.
Tandem (TNDM) to Expand Global Insulin Pump Base With New Buy
by Zacks Equity Research
The AMF Medical acquisition will help Tandem (TNDM) advance with its sustainability objectives by offering an additional pump that minimizes electronic and battery waste generation.